Company Visioneering Technologies, Inc.

Equities

VTI

AU000000VTI2

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Annual profits - Rate of surprise

Sector Glasses, Spectacles & Contact Lenses

Market Closed - Australian S.E. Other stock markets 11:56:29 2024-07-08 pm EDT			5-day change	1st Jan Change
0.135 ^AUD	+3.85%		-6.90%	-46.00%

May. 23	Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
Apr. 24	Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024

Visioneering Technologies, Inc. is a medical device company. The Company is primarily engaged in the design, manufacture, sale and distribution of a contact lens, the NaturalVue Multifocal 1 Day (NaturalVue MF) contact lens. The Company operates through two segments: North America and Europe / Asia-Pacific. The North America segment includes its operations in the United States and Canada. The Europe/Asia-Pacific segment includes its operations outside of North America. Its flagship product is the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lens for adults with Presbyopia and children with Myopia. The Company sells its contact lenses in the United States, Europe, Australia, New Zealand, Hong Kong, Singapore, Canada and Malaysia. The Company manages the warehousing and distribution of its products through a contract with a third-party logistics provider (the 3PL).

AUD in Million	2022	Weight	2023	Weight	Delta
Contact Lenses 100.0 %	11	100.0 %	13	100.0 %	+24.29%

AUD in Million	2022	Weight	2023	Weight	Delta
North America 93.1 %	10	93.0 %	12	93.1 %	+24.52%
Europe/Asia-Pacific 6.9 %	1	7.0 %	1	6.9 %	+21.34%

Managers	Title	Age	Since
Juan Aragon CEO	Chief Executive Officer	-	23-09-30
Brian D. Lane DFI	Director of Finance/CFO	62	18-12-09
Kuang-mon Tuan CTO	Chief Tech/Sci/R&D Officer	-	21-11-01
Heather Hale AUD	Comptroller/Controller/Auditor	-	17-12-14
Leanne Ralph SEC	Corporate Secretary	-	17-06-22

Members of the board	Title	Age	Since
Kathleen Miller CHM	Chairman	59	22-12-30
Allan Rubenstein BRD	Director/Board Member	79	22-06-28
Andrew Silverberg BRD	Director/Board Member	-	20-11-04
Juan Aragon CEO	Chief Executive Officer	-	23-09-30
Dwight Akerman BRD	Director/Board Member	-	21-07-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	52,378,773	43,965,786 ( 83.94 %)	0	83.94 %

Name	Equities	%	Valuation
Thorney Investment Group Australia Pty Ltd. 47.42 %	25,209,832	47.42 %	2 M $
Regal Funds Management Pty Ltd. 8.143 %	4,329,413	8.143 %	390 340 $
Paul Cozzi 4.324 %	2,298,789	4.324 %	207 259 $
Jean Franchi 2.251 %	1,196,500	2.251 %	107 876 $
Zita Peach 1.996 %	1,061,330	1.996 %	95 690 $
Altor Alpha Funds Management Pty Ltd. 1.284 %	682,842	1.284 %	61 565 $
Gavin J Dunhill 0.5455 %	290,000	0.5455 %	26 146 $
Brian D. Lane 0.4723 %	251,076	0.4723 %	22 637 $
Lawrence Gozlan 0.4426 %	235,295	0.4426 %	21 214 $
Minh V Q Dang 0.4172 %	221,813	0.4172 %	19 999 $

Visioneering Technologies, Inc.

30 Mansell Court Suite 215

30076, Alpharetta

http://www.vtivision.com

address Visioneering Technologies, Inc.(VTI)

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Glasses, Spectacles & Contact Lenses

	1st Jan change	Capi.
VISIONEERING TECHNOLOGIES, INC.	-46.00%	4.82M
ESSILORLUXOTTICA	+8.48%	98.9B
ALCON INC.	+22.24%	44.42B
THE COOPER COMPANIES, INC.	-9.90%	17.05B
AUTEK CHINA INC.	-33.13%	1.86B
WARBY PARKER INC.	+9.15%	1.84B
PEGAVISION CORPORATION	+7.69%	1.03B
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	-6.68%	674M
SHANGHAI CONANT OPTICAL CO., LTD.	+67.14%	646M
MENICON CO., LTD.	-44.17%	621M

Glasses, Spectacles & Contact Lenses